AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 291 min read$DGX

DELANEY MARK E sold $376K of DGX

DELANEY MARK E (SVP & Chief Commercial Officer) sold 1,600 shares of QUEST DIAGNOSTICS INC (DGX) at $235.18 ($0.38M total) on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DELANEY MARK E
Published Jul 29, 2026, 9:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DGX
Neutral
high confidence
Mentioned
$DGX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

Because the sale is open-market and pre-arranged under a 10b5-1 plan, it is generally not a strong standalone catalyst for trading decisions.

02

Market read

Traders may note the filing for completeness, but it does not introduce new fundamental information.

03

What to watch

The transaction size and the fact it is a planned 10b5-1 sale make it less informative than unscheduled sales or purchases tied to specific events.

Relevance 3/10Novelty 2/10Timing: as of the 2026-07-29 after SEC filing timestamp

Background

The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXNeutralHigh confidence
Context

Quest Diagnostics Form 4 shows SVP Mark E Delaney sold 1,600 shares on 2026-07-28 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal impact on DGX price; any effect is typically short-lived and outweighed by broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly pre-arranged under Rule 10b5-1, and provides no new company-specific operational or financial information.

Market effects

Sector

No direct read-across to diagnostics sector fundamentals from a single routine insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sales can sometimes reflect private risk perceptions, but the 10b5-1 pre-arrangement reduces interpretability.

Key entities

  • issuer
    Quest Diagnostics

    DGX, the company whose insider transaction is disclosed.

  • insider
    Delaney Mark E

    SVP and Chief Commercial Officer who sold shares.

  • trading_rule
    Rule 10b5-1 plan

    Pre-arranged plan that typically limits the informational value of the sale.

Read at source← All news

Related articles

JUL 27
$DGXMedAI 8/10

Why Quest Diagnostics Stock Climbed This Past Week

Quest Diagnostics (NYSE: DGX) shares rose over 8% last week after the company raised its full-year outlook. In Q2, revenue increased 10% to $3 billion, with adjusted EPS up 19% to $3.12. Quest projects full-year revenue around $12 billion and adjusted EPS of $11.05 to $11.25, citing growth and margin gains from automation and AI.

yahoo.com4 min
JUL 23
$DGXMedAI 9/10

Quest Diagnostics Boosts FY26 Outlook; Shares Up 5.7% - Update

Quest Diagnostics (DGX) reported Q2 results and raised its FY2026 guidance. It now expects GAAP earnings of $9.97 to $10.17 per share and adjusted earnings of $11.05 to $11.25, on revenue of $11.95B to $12.05B, versus prior ranges of $9.58 to $9.78, $10.63 to $10.83, and $11.78B to $11.90B. Shares were up 5.71% premarket.

rttnews.com2 min